[1]Bang DA, Andersen B, Thomsen VO. Rapid genotypic detection of rifampin- and isoniazid-resistant Mycobacterium tuberculosis directly in clinical specimens. J Clin Microbiol, 2006, 44(7):2605-2608.[2]Tortoli E, Marcelli F. Use of the INNO LiPA Rif. TB for detection of Mycobacterium tuberculosis DNA directly in clinical specimens and for simultaneous determination of rifampin susceptibility. Eur J Clin Microbiol Infect Dis, 2007, 26(1):51-55.[3]Lacoma A, Garcia-Sierra N, Prat C, et al. GenoType Mtb-DRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol, 2008, 46(11):3660-3667.[4]World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug resistant tuberculosis (MDR-TB). Geneva: WHO, 2008 [2009-11-18]. http://www.who.int/tb/dots/laboratory/lpa_policy.pdf.[5]Sohn H, Minion J, Albert H, et al. TB diagnostic tests: how do we figure out their costs? Expert Rev Anti Infect Ther, 2009, 7(6):723-733.[6]Kivihya-Ndugga LE, van Cleeff MR, Githui WA, et al. A comprehensive comparison of Ziehl-Neelsen and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting. Int J Tuberc Lung Dis, 2003, 7(12):1163-1171.[7]Sohn H, Sinthuwattanawibool C, Rienthong S, et al. Fluore-scence microscopy is less expensive than Ziehl-Neelsen microscopy in Thailand. Int J Tuberc Lung Dis, 2009,13(2):266-268.[8]Dowdy DW, Lourenco MC, Cavalcante SC, et al. Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS One, 2008, 3(12): e4057.[9]Foundation for Innovative New Diagnostics. FIND prices for GenoType MTBDRplus and Country List. Geneva:Foundation for Innovative New Diagnostics,2009[2012-12-20]. http://www.finddiagnostics.org/programs/find-negotiated-prices.[10]Ogwang S, Asiimwe BB, Traore H, et al. Comparison of rapid tests for detection of rifampicin-resistant Mycobacterium tuberculosis in Kampala, Uganda.BMC Infect Dis, 2009, 9: 139-146.[11]Acuna-Villaorduna C, Vassall A, Henostroza G, et al. Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis, 2008, 47(4): 487-495. |